Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
Conditions
Keywords
Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme
Brief summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Interventions
DRUGABT-414
ABT-414 will be administered by intravenous infusion
Sponsors
AbbVie
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation. * Health Care Provider (HCP) must have prior clinical trial experience with ABT-414. * The participant must not be eligible for an ABT-414 clinical trial. * Pediatric participants may be evaluated on a case by case basis.
Outcome results
None listed